1-3 of 3
L Voillat
Close
Sort by
Journal Articles

A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.

Ibrahim Yakoub-Agha, C. Hulin, C. Doyen, L. Benboubker, L. Voillat, K. Bouabdallah, G. Guillerm, P. Moreau, F. Maloisel, A.M. Stoppa, B. Pegourie, P. Rodon, M. Dib, P. Casassus, B. Slama, E. Voog, H. Jardel, P. Collet, M. Wettervald, A.M. Peny, P. Mineur, C. Duguet, R. Zerbib, T. Facon, J.Y. Mary
Journal: Blood
Blood (2005) 106 (11): 364.
https://doi.org/10.1182/blood.V106.11.364.364
Published: 2005
Journal Articles

Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Thierry Facon, J.Y. Mary, C. Hulin, L. Benboubker, M. Attal, M. Renaud, J.L. Harousseau, B. Pegourie, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, C. Martin, P. Casassus, J. Jaubert, H. Jardel, B. Kolb, F. Bauters
Journal: Blood
Blood (2005) 106 (11): 780.
https://doi.org/10.1182/blood.V106.11.780.780
Published: 2005
Journal Articles

Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? [letter; comment]

JY Cahn, M Flesch, A Brion, E Deconinck, MF Leconte Des Floris, L Voillat, E Plouvier, D Amsallem, P Tiberghien, T Fest
Journal: Blood
Blood (1992) 80 (8): 2149–2150.
https://doi.org/10.1182/blood.V80.8.2149.2149
Published: 1992